Revenue ($USD) : $14,813,000,000
R&D spend : $667,000,000
Employees : 60,000
Fiscal year end : 12/31/2023
CEO : José Almeida

www.baxter.com

Baxter continues to move forward with a separation of its Kidney Care business, which will be called Vantive. In mid-August it announced that it would sell Vantive to global investment firm Carlyle for $3.8 billion. The companies expect the transaction to close in late 2024 or early 2025, subject to customary approvals and closing conditions. “As a result of this proposed transaction, Baxter will emerge a more focused and more efficient company, better positioned to redefine healthcare delivery and advance innovation that benefits patients, customers and shareholders," Baxter Chair and CEO José Almeida said. Meanwhile, the Baxter Medical Products & Therapies business has benefitted from positive pricing and demand. The second quarter also saw the first U.S. sales of the Novum IQ large-volume infusion pump with Dose IQ safety software. –CN